High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
Abstract A remarkable proportion of neovascular age-related macular degeneration (nAMD) patients respond rather poorly to ranibizumab treatment, in spite of the minimum 4-week follow-up and treatment interval. Usually, retreatments are based on nAMD activity as evaluated by Spectral-domain Optical c...
Main Authors: | Cengiz Tuerksever, Christian Pruente, Katja Hatz |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-86348-2 |
Similar Items
-
Verteporfin photodynamic therapy combined with intravitreal ranibizumab in neovascular age-related macular degeneration: 24-month follow-up
by: Rosalia Giustolisi, et al.
Published: (2014-09-01) -
Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01) -
Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
by: Cvetkova NP, et al.
Published: (2016-06-01) -
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
by: Sam Razavi, et al.
Published: (2021-02-01) -
Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
by: Francisco Jose Rodriguez, et al.
Published: (2019-01-01)